On September 1-10, 2020, an assessment of the Global Fund's investments in HIV and TB programs in th

1-10 сентября 2020 года пройдет оценка инвестиций Глобального фонда в программы по ВИЧ и ТБ в КР
С 1-10 сентября 2020 года пройдет оценка инвестиций Глобального фонда в программы по ВИЧ и ТБ в КР
From September 1-10, 2020, an assessment of the Global Fund's investments in HIV and TB programs in Kyrgyzstan will be held.

An introductory meeting with national partners (members of the Committee to Combat HIV/AIDS, TB and Malaria and other partners working in the field of HIV and tuberculosis in the country) will take place on September 1.

The Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) commissioned APMG Health, Inc. (APMG) to conduct more than 100 unique assessments in 52 Focus countries and several countries in the Western Pacific region between July 2018 and 2020. The Global Fund will also be given a tool for evaluation and reporting. It is assumed that these independent assessments will be useful for countries in terms of
determining the progress that has been achieved in each specific area of the disease, adapting planned activities, as well as improving the effectiveness and level of impact of those already carried out. The results of the evaluations will be used to determine progress in achieving program goals, orient future investments and ongoing efforts to optimize the program at different levels, and provide information for decision-making in grant management, in particular when reviewing the grant or planning changes in implementation mechanisms where necessary. By clicking on the following link, you can get acquainted with the full list of countries in which the assessment will be conducted, and with the updated evaluation schedule:

https://tinyurl.com/focusedcountryschedule
Overall objective: To assess the effectiveness and impact of the Global Fund's investments in the Focus Areas

countries and the extent to which these investments have helped countries prepare sustainable
responses to these three diseases.
No comments yet. Be the first to add a comment!